These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Serum levels of miRNA-183 in patients with esophageal squamous cell carcinoma and its diagnostic value]. Author: Chen J, Chen M. Journal: Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Oct 28; 43(10):1048-1053. PubMed ID: 30523223. Abstract: To explore the changes of serum microRNA-183 levels in patients with esophageal squamous cell carcinoma (ESCC) and its clinical significance. Methods: Fifty-one patients with ESCC and 55 healthy subjects from Department of Cardiothoracic Surgery, Second Xiangya Hospital, Central South Unicersity were selected for this study. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to determine the level of miRNA-183 in serum samples. Chi-square test and correlation analysis were used to investigate the relationship between serum miRNA-183 level and clinical and pathological parameters of ESCC. Diagnostic efficiency of miRNA-183 and combined carcinoembryonic antigen (CEA) examination for ESCC was analyzed by receiver operating characteristic (ROC) curve. Results: 1) The levels of miR-183 in the patients with ESCC (4.47±1.54) were elevated compared with that in the healthy subjects (2.03±0.96), with significant difference (t=9.700, P<0.01). 2) The levels of serum miR-183 in ESCC patients were significantly different among patients with different TNM stages (χ2=4.049, P<0.01), which was not affected by gender, age, smoking, drinking, tumor location, tumor diameter, lymph node metastasis, depth of invasion and differentiation (all P>0.05). The levels of miR-183 were not associated with the serum CEA levels (P>0.05). 3) When the ROC curve analysis was used to diagnose ESCC with the optimal cutoff value of 4.502 for miR-183, the sensitivity, the specificity, the area under the curve (AUC) and 95% confidence interval was 78.9%, 76.2%, 0.762 and 0.830-0.922, respectively. When combined detection of serum miR-183 and CEA was used to diagnose ESCC, the sensitivity, specificity, AUC and 95% confidence interval was 82.3%, 92.6%, 0.877 and 0.814-0.935, respectively. Conclusion: Serum miRNA-183 levels in ESCC patients may be increased, which can improve the diagnostic efficiency of ESCC when combined with CEA. Serum miRNA-183 levels is related with tumor TNM stage, which contributes to the judgment of tumor progression and efficacy prediction. 目的:探讨食管鳞状细胞癌(esophageal squamous cell carcinoma,ESCC)患者血清的microRNA-183(miRNA-183)水平变化、临床意义及其对ESCC的诊断价值。方法:选择中南大学湘雅二医院胸外科住院治疗的51例ESCC患者及55例健康体检者血清标本作为研究对象。采用实时定量聚合酶链式反应(real-time quantitative polymerase chain reaction,RT-qPCR)测定血清标本miRNA-183表达水平;采用χ2检验及相关分析检测血清miRNA-183水平与ESCC临床及病理指标间的关联;采用受试者工作特征(receiver operating characteristic,ROC)曲线分析miRNA-183及其联合癌胚抗原(carcinoembryonic antigen,CEA)对ESCC的诊断效率。结果:1)MiR-183在健康体检者和ESCC患者中的相对表达量为(2.03±0.96)和(4.47±1.54),两者之间差异有统计学意义(t=9.700,P<0.01)。2)ESCC患者血清miR-183相对表达量在不同的肿瘤恶性程度分期中的差异有统计学意义(χ2=4.049;P<0.01);在不同性别、年龄、吸烟与否、饮酒与否、肿瘤部位、肿瘤直径、淋巴结转移、浸润深度、分化程度上差异均无统计学意义(均P>0.05);miR-183的相对表达量与血清CEA表达无关(P>0.05)。3)采用ROC曲线分析,以miR-183相对表达量4.502为诊断ESCC的最佳临界值,灵敏度为78.9%,特异度为76.2%,ROC曲线下面积(area under the curve,AUC)为0.762,95%置信区间为0.830~0.922。联合检测血清miR-183与CEA诊断ESCC,灵敏度为82.3%,特异性为92.6%,AUC为0.877,95%置信区间为0.814~0.935。结论:ESCC患者血清miRNA-183水平出现上调,血清miRNA-183与CEA联合测定可提高对ESCC的诊断效率。血清miRNA-183水平与肿瘤TNM分期有关,这有助于肿瘤病情进展判断和疗效预测。.[Abstract] [Full Text] [Related] [New Search]